中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01177 中国生物制药

交易中 07-08 13:27:57

4.920

+0.100

+2.07%

最高5.150	最低4.890	成交量1.31亿
今开4.970	昨收4.820	日振幅5.39%
总市值920.29亿	流通市值920.29亿	总股本187.05亿
成交额6.55亿	换手率0.70%	流通股本187.05亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":4.92,"timestamp":1783488475110,"preClose":4.82,"halted":0,"volume":130678598,"delay":0,"changeRate":0.020746887966804906,"floatShares":18705000000,"shares":18705000000,"eps":0.14969252248578713,"marketStatus":"交易中","change":0.1,"latestTime":"07-08 13:27:57","open":4.97,"high":5.15,"low":4.89,"amount":654716077,"amplitude":0.053942,"askPrice":4.93,"askSize":339000,"bidPrice":4.92,"bidSize":11000,"shortable":3,"etf":0,"ttmEps":0.14969252248578713,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1783498200000},"marketStatusCode":2,"adr":0,"listingDate":1070812800000,"exchange":"SEHK","adjPreClose":4.82,"dividendRate":0.021051,"openAndCloseTimeList":[[1783474200000,1783483200000],[1783486800000,1783497600000]],"volumeRatio":1.758683,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK","impliedVol":0.5212,"impliedVolPercentile":0.7265},"requestUrl":"/m/hq/s/01177","defaultTab":"news","newsList":[{"id":"2649027952","title":"葛兰素史克与中国生物制药深化战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2649027952","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649027952?lang=zh_cn&edition=full","pubTime":"2026-07-08 12:14","pubTimestamp":1783484047,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1191","GSK.UK","HK0000165453.HKD","IE00BZ08YT58.USD","GSKH","BK1515","IE00BZ08YS42.EUR","BK1521","LU1829250122.USD","01177","BK4585","BK1589","GSK","BK4532","BK4588","IE00BZ08YR35.GBP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127955732","title":"中国生物制药将负责相关产品在中国大陆的进口、分销等业务","url":"https://stock-news.laohu8.com/highlight/detail?id=1127955732","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127955732?lang=zh_cn&edition=full","pubTime":"2026-07-08 12:08","pubTimestamp":1783483683,"startTime":"0","endTime":"0","summary":"中国生物制药宣布，公司将负责特定产品在中国大陆市场的进口、分销及其他相关业务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1302929846.USD","HK0000165453.HKD","GSK.UK","LU0306807586.USD","LU1228905037.USD","LU0557290698.USD","LU1481599808.USD","LU0306806265.USD","SG9999001176.USD","LU1309081286.SGD","LU1400636491.USD","LU2468319806.SGD","LU1645745479.HKD","LU2646069778.SGD","BK1515","LU1035777561.USD","LU1983299246.USD","LU0321505439.SGD","LU1064927863.SGD","LU1202635105.USD","BK1191","LU0058720904.USD","BK5011","LU0985481810.HKD","01177","IE00BZ08YS42.EUR","LU1481600234.SGD","LU0161305163.EUR","LU0109981661.USD","IE00BQJZX424.USD","LU0321505868.SGD","IE0034235071.USD","LU0203347892.USD","LU2089984988.USD","LU0225284248.USD","LU1015430645.USD","LU0545562505.USD","IE00B3T34201.USD","LU1670756490.USD","IE00BZ08YT58.USD","LU0225771236.USD","BK1521","IE00BWDBJ516.SGD","LU1098665638.USD","LU1400636657.SGD","LU0987226296.USD","LU1046248800.SGD","LU0575583348.USD","BK1589","SG9999013999.USD","LU1487256676.USD","LU0971552673.USD","SGXZ57979304.SGD","LU1228905540.USD","IE00BZ08YR35.GBP","LU0211331839.USD","SG9999001176.SGD","LU1400636574.HKD","LU0203345920.USD","LU0289739699.SGD","LU0971552830.HKD","LU0225283273.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105036328","title":"中国生物制药获GSK慢阻肺双药中国商业化授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1105036328","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105036328?lang=zh_cn&edition=full","pubTime":"2026-07-08 12:06","pubTimestamp":1783483577,"startTime":"0","endTime":"0","summary":"中国生物制药已成功获得葛兰素史克旗下两款重磅慢性阻塞性肺疾病治疗药物——Trelegy Ellipta与Anoro Ellipta在中国的商业化权利。此举标志着这家中国领先的医药企业在呼吸疾病领域的产品管线与市场布局得到显著强化。此项合作不仅将提升中国生物制药在呼吸系统疾病领域的核心竞争力，也反映了跨国药企与中国本土龙头企业深化战略协作，共同开拓中国巨大医疗市场的新趋势。预计该授权将为中国生物制药的未来营收增长注入新的动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","BK1521","01177","BK1515","IE00BZ08YT58.USD","BK1191","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180615564","title":"中国生物制药深化与GSK在中国呼吸疗法领域的独家战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1180615564","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180615564?lang=zh_cn&edition=full","pubTime":"2026-07-08 12:06","pubTimestamp":1783483573,"startTime":"0","endTime":"0","summary":"中国生物制药宣布，将进一步深化与葛兰素史克在中国市场呼吸系统治疗领域的独家战略合作伙伴关系。此举旨在整合双方优势资源，共同推进创新呼吸疗法在中国的研发、商业化及市场准入，以应对国内日益增长的呼吸疾病诊疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YT58.USD","BK1521","01177","IE00BZ08YS42.EUR","BK1589","HK0000165453.HKD","BK1515","IE00BZ08YR35.GBP","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649072952","title":"中国生物制药：深化与GSK呼吸领域战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2649072952","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649072952?lang=zh_cn&edition=full","pubTime":"2026-07-08 12:06","pubTimestamp":1783483560,"startTime":"0","endTime":"0","summary":"【中国生物制药：深化与GSK呼吸领域战略合作】南财智讯7月8日电，中国生物制药（01177.HK）发布自愿公告，宣布其附属公司正大天晴药业集团股份有限公司进一步深化与葛兰素史克（GSK）于2026年5月达成的独家战略合作，获得GSK两款呼吸领域创新药——氟替美维吸入粉雾剂（商品名：全再乐）和乌美溴铵维兰特罗吸入粉雾剂（商品名：欧乐欣）在中国内地的商业化权益，包括进口、分销、医院准入及推广活动，相关销售收入全额确认为正大天晴营业收入。本次合作系双方继肝病领域后首次拓展至呼吸系统疾病，标志本集团呼吸管线从研发向商业化全面升级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607083798154841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK4532","BK4007","HK0000165453.HKD","BK1589","IE00BZ08YT58.USD","01177","BK1191","BK1521","GSK.UK","GSK","IE00BZ08YR35.GBP","BK4588","IE00BZ08YS42.EUR","BK4585","LU1829250122.USD","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192673365","title":"中国生物制药（01177）与葛兰素史克深化合作 获两款呼吸创新药内地独家商业化权益","url":"https://stock-news.laohu8.com/highlight/detail?id=1192673365","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192673365?lang=zh_cn&edition=full","pubTime":"2026-07-08 12:05","pubTimestamp":1783483530,"startTime":"0","endTime":"0","summary":"2026年7月8日，中国生物制药有限公司公告，其附属公司正大天晴药业集团股份有限公司已与葛兰素史克进一步深化2026年5月达成的独家战略合作，取得氟替美维吸入粉雾剂及乌美溴铵维兰特罗吸入粉雾剂在中国内地的商业化权益。公告显示，此次合作使中国生物制药与GSK的合作领域由肝病扩展至呼吸系统疾病，并在中国呼吸市场新增两款重磅药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117330724","title":"港股创新药概念股普涨，中国生物制药涨超6%，荣昌生物涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1117330724","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117330724?lang=zh_cn&edition=full","pubTime":"2026-07-08 09:45","pubTimestamp":1783475127,"startTime":"0","endTime":"0","summary":"7月8日，港股创新药概念股普涨，$中国生物制药(01177)$涨超6%，$荣昌生物(09995)$、$再鼎医药(09688)$涨超4%，$恒瑞医药(01276)$、$四环医药(00460)$，$康方生物(09926)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK4585","LU1064131003.USD","688331","LU1969619763.USD","LU2488822045.USD","BK4588","BK1191","IE00BZ08YR35.GBP","MEDX","LU2148510915.USD","BK1589","LU2328871848.SGD","BK0239","159992","HK0000165453.HKD","KCAI","09995","01177","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","BK1521","BK1574","LU1064130708.USD","06978","BK1583","VXUS","BK1161","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177338592","title":"异动解读 | 中国生物制药盘中大涨5.39%，与阿斯利康达成重磅授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1177338592","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177338592?lang=zh_cn&edition=full","pubTime":"2026-07-08 09:34","pubTimestamp":1783474499,"startTime":"0","endTime":"0","summary":"中国生物制药今日盘中股价大幅上扬，涨幅达到5.39%，引起了市场的热烈关注。消息面上，此次股价异动主要源于公司发布的一则重大利好消息。中国生物制药宣布，其附属公司正大天晴药业已与全球领先的跨国药企阿斯利康就自主研发的PDE3/4抑制剂TQC3721订立了独家授权协议。此次合作是公司继今年2月与赛诺菲达成授权合作后，年内与跨国制药企业达成的第二项授权合作。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649464959","title":"港股异动 | 中国生物制药(01177)早盘涨超4% 附属与阿斯利康就TQC3721订立独家授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2649464959","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649464959?lang=zh_cn&edition=full","pubTime":"2026-07-08 09:33","pubTimestamp":1783474437,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国生物制药早盘涨超4%，截至发稿，涨3.94%，报5.01元，成交额8286.17万港元。消息面上，7月8日，中国生物制药发布公告，集团附属公司正大天晴药业集团股份有限公司已与阿斯利康就集团自主研发的PDE3/4抑制剂订立独家授权协议。根据协议条款，集团将授予阿斯利康在中国以外地区开发、生产及商业化TQC3721的独家许可。阿斯利康还将获得TQC3721特定开发方案的全球独家许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2237443622.USD","BK1191","LU2237443549.SGD","HK0000165453.HKD","IE00BZ08YR35.GBP","BK1521","LU0058720904.USD","LU2089984988.USD","BK4568","BK1515","LU0320765992.SGD","LU0310800379.SGD","LU2237443978.SGD","IE00BZ08YS42.EUR","LU0708994859.HKD","LU2468319806.SGD","BK4588","VXUS","LU2237443382.USD","LU2456880835.USD","IE00B3T34201.USD","LU1829250122.USD","LU0889565916.HKD","LU0432979614.USD","LU1267930573.SGD","KCAI","LU2236285917.USD","LU2237443895.HKD","IE00BZ08YT58.USD","LU2417539215.USD","LU0109394709.USD","BK4007","BK1589","AZN","BK4585","LU2462157665.USD","01177","LU0128525929.USD","LU2237443465.HKD","LU0029864427.USD","LU0289739699.SGD","AZNH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132389637","title":"异动解读｜中国生物制药盘中上涨3.73%，与阿斯利康达成最高19亿美元授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1132389637","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132389637?lang=zh_cn&edition=full","pubTime":"2026-07-08 09:32","pubTimestamp":1783474326,"startTime":"0","endTime":"0","summary":"7月8日，中国生物制药盘中上涨3.73%，报5.03港元/股，成交额6303.0万港元。消息面上，公司公告其附属公司正大天晴药业与阿斯利康签署关于自主研发PDE3/4抑制剂TQC3721的独家授权协议。根据协议，公司将授予阿斯利康在中国以外地区开发、生产及商业化TQC3721的独家许可，阿斯利康将支付2亿美元首付款，满足后续开发、监管及销售里程碑条件后，总对价最高可达19亿美元，并包含分级特许权使用费。该交易彰显公司创新药管线的全球价值，与当前中国创新药BD交易金额超预期增长的行业趋势相吻合。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649680953","title":"中国生物制药(01177.HK)与阿斯利康就TQC3721订立独家授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2649680953","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649680953?lang=zh_cn&edition=full","pubTime":"2026-07-08 06:37","pubTimestamp":1783463835,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000165453.HKD","BK1521","BK1191","BK1515","IE00BZ08YS42.EUR","BK1589","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159813858","title":"中国生物制药（01177）授出TQC3721海外独家许可 最高对价可达19亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1159813858","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159813858?lang=zh_cn&edition=full","pubTime":"2026-07-08 06:06","pubTimestamp":1783461996,"startTime":"0","endTime":"0","summary":"2026年7月8日，中国生物制药有限公司公告称，其附属公司正大天晴药业集团股份有限公司已与阿斯利康签署关于自主研发的PDE3/4抑制剂TQC3721的独家授权协议。根据协议，中国生物制药将授予阿斯利康在中国以外地区开发、生产及商业化TQC3721的独家许可，并就特定开发方案给予全球独家许可。阿斯利康将向中国生物制药支付2亿美元首付款；在满足后续开发、监管及销售里程碑条件后，双方约定的总对价最高可达19亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100297612","title":"中国生物制药——可获2亿美元首付款、高达19亿美元里程碑付款及分级特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1100297612","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100297612?lang=zh_cn&edition=full","pubTime":"2026-07-08 06:06","pubTimestamp":1783461964,"startTime":"0","endTime":"0","summary":"中国生物制药在许可协议中，有资格获得高达19亿美元的里程碑付款及分级特许权使用费，同时还可获得2亿美元的首付款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001176.USD","LU0310799852.SGD","LU0661504455.SGD","LU0784383803.USD","LU0784385170.HKD","LU0823416689.USD","IE00BJT1NW94.SGD","LU0957799991.USD","LU0823399737.USD","LU1989772840.SGD","LU0963555726.SGD","LU1267930227.SGD","LU0920783379.SGD","LU1104425308.USD","LU0757432116.USD","LU0784384876.USD","LU1496350502.SGD","LU2089283258.USD","LU2357627491.SGD","LU0920840948.USD","LU0997586515.USD","LU2433249047.HKD","LU1153584641.USD","LU2355687059.USD","LU2112291526.USD","LU0171276677.USD","LU0047473722.SGD","LU0496365809.HKD","IE00BJJMRZ35.SGD","LU0784385840.USD","LU1923622614.USD","LU0792757196.USD","LU1019632923.USD","LU1481600234.SGD","LU1291159041.SGD","LU1989772923.USD","LU2468319806.SGD","LU1196032939.SGD","LU1015430645.USD","LU1064927863.SGD","LU1261432733.SGD","LU1829250122.USD","IE00BFTCPJ56.SGD","LU0997586432.USD","LU1046234339.USD","LU0310800965.SGD","LU1989771016.USD","LU0158827948.USD","LU1273509221.SGD","LU0949170772.SGD","LU0390134368.USD","LU0211326755.USD","LU0882574055.USD","LU0047473722.EUR","LU0526926950.USD","SG9999013999.USD","LU0211327993.USD","LU1019634622.SGD","LU2237443549.SGD","LU0310800379.SGD","LU2133065610.SGD","IE00B4R5TH58.HKD","LU2279689827.SGD","LU2114397693.USD","LU1323610961.USD","LU1267930813.SGD","LU0077335932.USD","LU2237443382.USD","LU2023251221.USD","LU2125909247.SGD","IE00B2B36J28.USD","LU2539964713.USD","LU0345777147.USD","LU0575583348.USD","LU1880407132.USD","LU0964806797.USD","LU0969580561.USD","LU1496350171.SGD","LU2091194634.USD","LU0972486137.USD","LU2324357040.USD","LU1301847155.USD","LU0889565080.SGD","LU1153585028.USD","LU1170363599.USD","LU0949170426.SGD","LU2293690249.USD","IE00B3T34201.USD","LU0211326839.USD","LU1119994496.HKD","LU0499090636.EUR","IE0002141913.USD","LU2237443895.HKD","LU0557290698.USD","IE00BZ08YS42.EUR","LU1003076772.USD","LU0052756011.USD","IE0009355771.USD","LU2089284900.SGD","LU0640478417.SGD","LU0211328371.USD","LU0114720955.EUR","LU1355424745.HKD","LU0171293334.USD","LU2125909593.SGD","LU1003077747.HKD","LU1023059063.AUD","LU2237443622.USD","LU0266013472.USD","LU0976567544.SGD","IE00BZ08YR35.GBP","LU0553294199.USD","LU0887340254.USD","LU0203345920.USD","LU0432979614.USD","LU1814569148.SGD","LU0827474353.SGD","BK1589","LU1057294990.SGD","LU0708994859.HKD","LU0011850046.USD","LU0738911758.USD","LU1481599808.USD","SGXZ57979304.SGD","LU1084165304.USD","LU2293690082.USD","LU0289739699.SGD","LU1051770623.HKD","LU0889566641.SGD","IE0034235188.USD","LU2108987350.USD","LU0345777659.USD","LU1487256676.USD","LU0960981461.USD","BK1191","LU0203347892.USD","LU1267930490.SGD","BK1515","LU0128525689.USD","LU0128525929.USD","LU0545039389.USD","LU0857590862.USD","01177","HK0000165453.HKD","LU0058720904.USD","AZN.UK","LU2089984988.USD","LU1078025761.USD","LU2237443978.SGD","BK1521","LU1267930573.SGD","BK5011","03165","IE00BKPKM643.USD","LU2237443465.HKD","LU1061106388.HKD","LU0122379950.USD","IE00BZ08YT58.USD","SG9999001176.SGD","LU0859254822.USD","LU1880407215.USD","LU1983299246.USD","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103727001","title":"异动解读｜中国生物制药盘中下跌3.17%，报4.89港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103727001","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103727001?lang=zh_cn&edition=full","pubTime":"2026-07-07 13:14","pubTimestamp":1783401270,"startTime":"0","endTime":"0","summary":"7月7日，中国生物制药盘中下跌3.17%，报4.89港元/股，成交额1.8亿港元。中国生物制药所在的制药行业中，整体表现疲软，个股中，石药集团跌3.89%，翰森制药跌3.18%，恒瑞医药跌1.98%，联邦制药跌3.18%，凯莱英跌3.65%。中国生物制药有限公司是一家主要从事制药业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂及西药产品业务。投资分部主要从事长期投资业务。其他分部主要从事相关医疗及医院业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649648782","title":"港股早盘反复扬升 恒指半日涨0.83% 中国生物制药(01177)涨7.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649648782","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649648782?lang=zh_cn&edition=full","pubTime":"2026-07-06 12:18","pubTimestamp":1783311529,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股早盘反复扬升，截至午间收盘，恒指涨0.83%，国企指数涨1.1%，恒生科技指数涨1.16%。中国生物制药涨7.17%，快手-W涨5.35%，康师傅控股涨4.12%，中国宏桥涨4.12%，京东健康涨3.93%，极兔速递-W涨3.89%。创新药概念走强，海西新药涨7.52%，诺诚健华涨7.49%，中国生物制药涨7.17%，同源康医药-B涨5.73%，康哲药业涨5.64%，康诺亚-B涨5.35%。存储芯片方面，上周DDR5现货价格涨势趋缓，NAND价格保持上涨。华泰证券表示，上周港股下跌趋势暂缓，市场高低切讨论升温。","market":"other","thumbnail":"https://static.szfiu.com/news/20210625/OWQ4NGY3MGJmOTZjMTUwZjdhOTdjYjQwNjE1MDM0NDE4NQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/OWQ4NGY3MGJmOTZjMTUwZjdhOTdjYjQwNjE1MDM0NDE4NQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985165","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK1515","01177","IE00BZ08YT58.USD","BK1191","BK1521","HK0000165453.HKD","SBHMY","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649064816","title":"港股午评：恒指涨0.83% 科指涨1.16% 科网股普涨 电力设备股强势 PCB概念股下挫 快手涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649064816","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649064816?lang=zh_cn&edition=full","pubTime":"2026-07-06 12:00","pubTimestamp":1783310400,"startTime":"0","endTime":"0","summary":"　　7月6日消息，港股三大指数集体上涨。截至午间收盘，恒生指数涨0.83%，报23542.97，恒生科技指数涨1.16%，国企指数涨1.1%。盘面上，科网股普涨，快手涨超5%，腾讯涨超3%，美团、网易、小米涨超2%；电力设备股涨幅居前，东方电气涨超7%；创新药概念股活跃，中国生物制药涨超7%；PCB概念股下挫，建滔积层板跌超9%。半导体行业研究机构SemiAnalysis今日上午在社交平台发布一系列文章，指出英伟达Kyber NVL144机架架构或将遭遇延迟。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-06/doc-inifvuye8584281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["513600","BK1575","LU0329678170.USD","IE00BF5LJ272.USD","LU1917777945.USD","LU2087589342.USD","07226","LU0456842615.SGD","LU0737861699.HKD","LU1282649141.HKD","LU0269904917.USD","LU0588545904.SGD","IE00B067MR52.USD","SOCL","LU0067412154.USD","07500","IE00B3M56506.USD","LU0708995583.HKD","FDNI","LU0871576103.HKD","LU0882747503.HKD","LU0096374516.USD","LU0633140727.USD","LU0577902611.USD","LU0329678337.USD","BK1615","LU0315178854.USD","IE00B29SXG58.USD","LU0307460666.USD","BK1589","KWEB","LU1568876251.USD","LU0979878070.USD","HK0001040143.USD","LU1282651048.USD","LU0823397285.USD","03032","LU1008478684.HKD","LU1282648689.USD","01072","LU0878005551.USD","LU1242518931.SGD","LU1196710195.USD","LU2251237488.HKD","LU0831103253.SGD","LU0052750758.USD","SG9999014914.USD","LU1282649067.USD","LU0164872284.USD","BK1515","HK0000151867.HKD","LU0683595622.HKD","LU2152927971.USD","HK0000306701.USD","BK1531","LU2242644610.SGD","LU1044876610.USD","SGXZ99366536.SGD","LU1023057109.AUD","SGXZ51526630.SGD","LU0043850808.USD","LU0516423091.SGD","LU0348766576.USD","LU1226288097.SGD","LU0326950275.SGD","LU1064131003.USD","LU1568876335.HKD","LU1974910355.USD","ODDS","LU1152091168.USD","LU0210527791.USD","LU0054450605.USD","LU0856984785.SGD","LU0348783662.USD","LU0588546209.SGD","03419","LU2247934214.USD","LU0700851271.USD","LU0828237940.HKD","IE0034224299.USD","LU1481107354.HKD","LU2051468812.USD","LU0080751232.USD","LU1831875114.USD","02833","IE0008368411.USD","LU1196710864.SGD","LU0140636845.USD","IE00B5MMRT66.SGD","GB00BDT5M118.USD","LU2237443549.SGD","LU1688375341.USD","LU0211331839.USD","MCHmain","LU0823041008.USD","LU1226288170.HKD","IE00BQXX3C00.GBP","LU1691799644.USD","LU1044874839.SGD","LU0737861772.HKD","LU2237443895.HKD","LU0577902454.USD","SG9999006514.SGD","IE00BZ08YT58.USD","LU0431992006.USD","HK0000165453.HKD","LU0577902371.SGD","LU0890818403.SGD","LU2476274720.SGD","SGXZ81514606.USD","IE00B031HY20.USD","LU0210526637.USD","09115","LU2362541273.HKD","LU0049112450.USD","LU0326948709.USD","SG9999002562.SGD","LU0561508036.HKD","LU1769817179.HKD","LU2237443382.USD","SG9999018857.SGD","LU1226288253.USD","LU0499858602.USD","LU0828237510.HKD","LU2097828805.USD","LU2187417386.USD","LU0898667661.SGD","BKF","LU1719994722.HKD","82800","LU0029875118.USD","LU0061477393.USD","IE00B0169L03.USD","SG9999017495.SGD","SG9999004220.SGD","LU0327786744.USD","LU1303224171.USD","IE00B8HQ1Z84.USD","LU1880383440.USD","SG9999001846.SGD","LU2097828631.EUR","LU0011963245.USD","LU0642271901.SGD","LU0072462343.USD","LU0572940350.SGD","LU2351347302.SGD","BK1502","LU0675040207.SGD","LU0588545490.SGD","LU0607220059.USD","BK1521","LU2045819591.USD","SG9999014906.USD","JEMA","LU0047713382.USD","LU0502904849.HKD","LU0149534421.HKD","HK0001040168.HKD","LU0359201885.HKD","LU2125910500.SGD","SG9999014880.SGD","BK1610","IE00B031HW06.USD","LU0106259558.USD","LU1251922891.USD","LU0264606111.USD","LU0823413660.USD","LU2237443622.USD","LU2265009873.SGD","LU1961090484.USD","LU0819121731.USD","LU0287142896.SGD","SG9999018865.SGD","LU1733274390.USD","IE00B543WZ88.USD","LU0054237671.USD","LU1770034418.SGD","IE00B8L5B284.USD","LU2929501877.USD","LU0738912210.USD","LU1046422090.SGD","LU2226246903.HKD","LU0210533765.USD","IE00B0JY6N72.USD","LU0348827113.USD","LU0196878994.USD","LU0543330566.HKD","HK0000914660.USD","LU1102505929.USD","LU0228367735.SGD","LU0650527681.SGD","LU1439102457.SGD","SG9999013353.USD","SG9999001051.SGD","LU2008162690.USD","LU2097828557.USD","LU2023250504.SGD","LU0449509016.USD","LU1323998911.USD","BK1608","BK1609","LU0878004406.USD","LU2498475776.HKD","LU0359201612.USD","CXSE","LU0651947912.USD","03423","LU0605514214.HKD","SG9999015945.SGD","LU0348767384.USD","LU2362540622.SGD","LU0823413587.USD","LU0572939691.SGD","LU0972618739.USD","LU0499858438.USD","LU1152091754.HKD","LU0127658192.USD","LU2237443978.SGD","LU0918141705.HKD","LU0463099449.HKD","LU1734074674.USD","LU0384037296.USD","BK1170","LU0289960550.SGD","HTCD.SI","HK0000352291.HKD","LU1804176565.USD","LU1807302812.USD","LU0143863198.USD","LU0543330483.HKD","LU1810669033.SGD","BK1516","HK0000306685.HKD","LU0417516571.SGD","LU3227948356.SGD","LU0791591158.USD","IE00B0169N27.USD","LU0823426308.USD","LU0608807433.USD","LU0868486357.SGD","HK0000352382.USD","LU1868837565.USD","TCEHY","LU0048388663.USD","IE0003795394.USD","LU2293587155.HKD","IE0031814852.USD","LU0048580855.USD","LU0862451837.USD","LU1868837722.USD","SG9999015952.SGD","LU0509642566.USD","03115","LU0456827905.SGD","LU0516422952.EUR","LU0531971595.HKD","LU0823426480.USD","JADE","TCHI","BK1205","LU0320764599.SGD","LU0488056044.USD","LU0259732245.USD","LU1048596156.SGD","LU1504937902.USD","LU1051769294.HKD","SG9999001903.USD","LU0173614495.USD","IE0003895053.USD","LU0345776255.USD","SG9999001689.USD","XSOE","LU2399975544.HKD","02800","LU0828238088.HKD","LU2133065610.SGD","BK1546","LU1224444064.USD","LU0348783233.USD","LU2476274308.USD","LU0797268264.HKD","LU0608807946.USD","01024","LU2106854487.HKD","IE0008368742.USD","LU0229945570.USD","LU0203347892.USD","LU1224709979.USD","09067","SG9999001226.SGD","LU1880383366.USD","LU0175139822.USD","LU0348825331.USD","LU1282651121.HKD","03037","BK1522","BK1591","01888","LU0611395673.USD","SG9999015986.USD","LU1044875133.USD","LU1115378108.SGD","LU0540923850.HKD","SG9999000327.SGD","LU0244354667.USD","SG9999006597.SGD","LU1718418525.SGD","LU0345775950.USD","LU0823039010.USD","LU0414403682.SGD","LU1960683339.HKD","LU1813983027.USD","LU0640798160.USD","LU0455707207.USD","LU0359202008.SGD","LU3063872942.SGD","LU2125910849.SGD","IE00BQXX3F31.USD","LU2317271919.USD","LU0541502299.USD","LU0231483743.USD","LU0456846285.SGD","ESPO","LU1102505762.USD","LU0918141887.USD","03417","07552","LU0648948544.HKD","SG9999002463.SGD","600875","LU1785774172.SGD","LU0588545730.USD","LU0880133367.SGD","SG9999002828.SGD","IE00BZ08YS42.EUR","LU0106959298.USD","BK1586","01177","LU1051768304.USD","SG9999001093.SGD","SG9999014898.SGD","LU0348788117.USD","LU2097828714.EUR","LU0128522744.USD","LU0651946864.USD","IE00BPRC5H50.USD","BK1095","MCHS","LU1226287875.USD","LU1883866441.USD","LU1439103000.SGD","07200","LU0039217434.USD","LU0228659784.USD","LU0593848301.USD","LU0823040885.USD","LU1951186391.HKD","BIDD","LU0315179316.USD","LU0396098781.USD","LU0784639295.USD","LU1328277881.USD","LU1048484197.HKD","LU1211504680.USD","LU2251237306.USD","LU2462611646.USD","LU0823397103.USD","FPA","SG9999003461.SGD","LU2449936058.SGD","03067","LU1235295612.USD","SG9999000459.SGD","IE0008369823.USD","BK1506","LU0261950983.USD","LU0084288322.USD","LU1316542783.SGD","LU1675838814.USD","IE0001KFT4U8.USD","02837","03088","LU1242518857.USD","LU0531970944.HKD","SG9999000418.SGD","LU1993786604.SGD","LU0821914370.USD","LU0577902298.EUR","03033","LU0572944931.SGD","LU0106252389.USD","LU1188198961.HKD","LU2039709279.SGD","BK1191","LU0235996351.USD","LU1642822792.SGD","HK0000320264.USD","LU0211977185.USD","LU0791590937.USD","LU1814569148.SGD","83115","LU0348805143.USD","LU0516423174.USD","LU1720050803.USD","LU2362541513.USD","LU2294711473.HKD","LU0214875030.USD","LU0594300179.USD","HK0000320223.HKD","SG9999001069.SGD","LU0164865239.USD","LU2148510915.USD","LU1733274473.HKD","LDEM","LU0164880469.USD","LU1981816686.USD","SG9999014674.SGD","LU0107464264.USD","LU0348735423.USD","LU1655091459.SGD","IE00BZ08YR35.GBP","LU2257852520.SGD","BK1526","LU1282649810.SGD","LU0708995153.HKD","LU1629966141.USD","LU0320764755.SGD","LU0251144936.SGD","LU1226287529.USD","LU0051755006.USD","BK1590","LU0672654166.SGD","LU0589944569.HKD","81024","LU0633140560.USD","LU0254981946.USD","LU1048588211.SGD","LU0370786039.SGD","LU0048597586.USD","LU0441854154.USD","LU0541501648.USD","LU0985320562.USD","IE0003851619.USD","LU0072913022.USD","LU0634319403.HKD","LU1366334578.USD","LU0070217475.USD","LU0516422366.SGD","IE00B97KM107.HKD","LU1794554557.SGD","BK1618","LU0261947096.USD","LU0328353924.USD","LU0594300419.USD","LU0449515922.USD","IE00B031J352.USD","LU0348816934.USD","LU0862451753.SGD","LU0348784397.USD","LU0516422440.USD","LU1956131251.USD","LU0163747925.USD","LU0192582467.USD","LU0345769128.USD","LU0132412106.USD","LU2177674079.SGD","LU1196710351.USD","LU0169518387.USD","LU0149721374.USD","LU0143863784.USD","LU1105468828.SGD","LU2279701549.SGD","LU0029874905.USD","LU1328615791.USD","LU0577902538.SGD","LU0348723411.USD","LU0348814723.USD","LU2097828474.EUR","HSI","LU0873338254.USD","FFEM","LU1366334651.USD","LU1226287792.SGD","IE00BGV7N243.SGD","SG9999015978.USD","SBHMY","HSTECH","LU0865486749.SGD","LU1770036033.HKD","LU0117844026.USD","EMC","TCHmain","IE0032834883.USD","LU0320764243.SGD","LU0181495838.USD","LU0469268626.HKD","BK1517","LU0501845795.SGD","LU0823038988.USD","SGXZ90724238.SGD","00700","LU0417516902.SGD","LU1064130708.USD","SG9999007991.SGD","AAXJ","LU0417516738.SGD","LU0786609619.USD","LU1515016050.SGD","IE00BQXX3D17.EUR","HHImain","LU1808992512.USD","LU1769817096.USD","IE0032431581.USD","LU0188438112.USD","LU0128522157.USD","LU0819123356.HKD","LU0293314216.USD","LU0314109678.HKD","07300","LU1725190679.HKD","LU0203345920.USD","LU2237443465.HKD","LU0886674414.USD","LU0049853897.USD","SGXZ31699556.SGD","IE0009570106.USD","09088","LU0117841782.USD","LU0165289439.USD","LU2778985437.USD","HK0000914686.HKD","LU0345769631.USD","LU1868838027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649571617","title":"【特约大V】邓声兴：非农远逊降温加息预期，恒指或随科网股反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=2649571617","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649571617?lang=zh_cn&edition=full","pubTime":"2026-07-06 09:57","pubTimestamp":1783303058,"startTime":"0","endTime":"0","summary":"迅策折让13%配股及发行13.6亿元人民币可转换债券，跌5.3%，报117.3元。道指周五为独立假期，全日休市。非农远逊降温加息预期，恒指或随科网股反弹。中国生物制药公司2025年全年收入318.3亿元人民币，按年增长10.3%，归母净利润23.4亿元，按年增长22.0%，经调整Non-HKFRS归母净利润达45.4亿元，按年增长31.4%。管理层对2026至2027年产品收入每年增长10%至11%充满信心。此前该适应症已于5月22日纳入优先审评审批程序。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/ZjliN2ZkODRiNzhhNzU2YzM1OTEzZDg3ZjhhMTI3MDQ3NzI4ODg1.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZjliN2ZkODRiNzhhNzU2YzM1OTEzZDg3ZjhhMTI3MDQ3NzI4ODg1.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985152","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07200","BK1521","03419","07300","07500","03115","BK1515","IE00BZ08YR35.GBP","02800","01177","HHImain","BK1191","IE00BZ08YT58.USD","BK1589","02833","HSI","09115","IE00BZ08YS42.EUR","513600","HK0000165453.HKD","82800","HSTECH","MCHmain","03037","83115","SBHMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119580623","title":"异动解读 | 中国生物制药盘中大涨5.06%，新药获批与医保利好成主要推手","url":"https://stock-news.laohu8.com/highlight/detail?id=1119580623","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119580623?lang=zh_cn&edition=full","pubTime":"2026-07-06 09:44","pubTimestamp":1783302284,"startTime":"0","endTime":"0","summary":"中国生物制药今日盘中股价大幅上扬，涨幅达到5.06%，表现显著强于市场。消息面上，公司近期利好频传。首先，其附属公司北京潮药业的盐酸罗哌卡因缓释溶液新药上市申请已获得国家药监局受理，该药物用于成人术后长效镇痛，为公司产品管线注入新的增长动力。综合来看，新药研发进展、有利的行业政策环境以及公司积极的资本运作共同构成了此次股价上涨的核心驱动力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648652835","title":"中国生物制药(01177.HK)：盐酸罗哌卡因缓释溶液上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2648652835","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648652835?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:34","pubTimestamp":1783067681,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BZ08YT58.USD","BK1589","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","HK0000165453.HKD","BK1191","01177","BK1515","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105208747","title":"异动解读｜中国生物制药盘中上涨4.76%，医保目录调整利好创新药企","url":"https://stock-news.laohu8.com/highlight/detail?id=1105208747","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105208747?lang=zh_cn&edition=full","pubTime":"2026-07-03 09:40","pubTimestamp":1783042810,"startTime":"0","endTime":"0","summary":"7月3日，中国生物制药盘中上涨4.76%，报4.79港元，成交额8856.93万港元。消息面上，国家医保局近日公示了通过基本医保目录及商保创新药目录调整初步形式审查的药品名单，本次形式审查呈现申报品种数量提高、通过率大幅提升、以新药为主等特征，叠加首次引入的\"预申报\"机制，充分体现医保目录调整对创新药的持续倾斜。中信建投研报看好相关创新药及制药企业的医保准入与商保增量空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":0.093},{"period":"1month","weight":0.0462},{"period":"3month","weight":-0.1929},{"period":"6month","weight":-0.2809},{"period":"1year","weight":-0.1079},{"period":"ytd","weight":-0.2111}],"compareEarnings":[{"period":"1week","weight":0.0269},{"period":"1month","weight":-0.0587},{"period":"3month","weight":-0.0925},{"period":"6month","weight":-0.1014},{"period":"1year","weight":-0.0164},{"period":"ytd","weight":-0.0832}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一家主要从事制药业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂及西药产品业务。投资分部主要从事长期投资业务。其他分部主要从事相关医疗及医院业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.434783,"avgChangeRate":0.007657},{"month":2,"riseRate":0.652174,"avgChangeRate":0.056403},{"month":3,"riseRate":0.565217,"avgChangeRate":0.046203},{"month":4,"riseRate":0.478261,"avgChangeRate":0.020807},{"month":5,"riseRate":0.695652,"avgChangeRate":0.037978},{"month":6,"riseRate":0.347826,"avgChangeRate":0.004739},{"month":7,"riseRate":0.652174,"avgChangeRate":0.050272},{"month":8,"riseRate":0.409091,"avgChangeRate":-0.010627},{"month":9,"riseRate":0.409091,"avgChangeRate":-0.014397},{"month":10,"riseRate":0.545455,"avgChangeRate":0.024699},{"month":11,"riseRate":0.5,"avgChangeRate":0.067223},{"month":12,"riseRate":0.409091,"avgChangeRate":-0.012172}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SBP GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}